Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
about
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impactManagement of Hepatitis C Post-liver Transplantation: a Comprehensive ReviewChallenges of recurrent hepatitis C in the liver transplant patientMicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation.Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.Recurrent hepatitis C after liver transplantNatural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.Major challenges limiting liver transplantation in the United States.Prevention of hepatitis C recurrence after liver transplantation: An update.Living-donor liver transplantation and hepatitis CRacial differences in fibrosis progression after HCV-related liver transplantation.Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences.Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.Recurrent HCV after liver transplantation-mechanisms, assessment and therapy.A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C.Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation.Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.Of mice and men, calcineurin inhibitors and hepatitis C.Hot topic in hepatitis C virus research: the type of immunosuppression does not matter.Liver transplantation and hepatitis C
P2860
Q22299128-6239ABF7-FFB6-4C88-AFA4-98CCC7C171AAQ26781741-B2ADE629-5CE6-4658-B042-AD35C5B72728Q27011871-3891D8C4-69E8-402F-A993-D424D5F87673Q30456389-1E1361C6-046D-4186-9E5B-A040E16C87FCQ30560759-CD671F07-4CCB-4663-9899-83CF60924F98Q34067825-D545A714-B56C-46EF-B166-A2A2E644ED22Q34093754-63816CF8-4121-4CD5-8438-2028DB2915F4Q34150039-1A463D26-BE62-4774-B353-A14ACE3913CBQ34168552-E1E3FD7C-5955-4746-8A60-61785C997BD9Q35194675-A58D7D7F-922E-4388-B061-892F57A483EAQ36220172-A3C16990-E840-4A2B-89E8-6C32B025DAA8Q36587253-4D2B3D8A-B846-4C6A-82FE-06D39A0C4AE6Q36760718-B5754B9A-E1CA-421B-A38D-93D61B9C8074Q37355472-7DBA7A94-8EC8-418A-AB9C-7DADE43C45F6Q37962197-D01C6924-1F77-46CA-8A15-0856EA48190DQ37973516-A0ECA6AE-FAD4-491A-B932-D478B3DD6C2FQ38057373-91764F0C-5852-4CD2-ABB5-1629558817F4Q38061056-342D20FB-1342-4D3A-AE12-F0DD8085AFD3Q38081919-1FA524EE-5199-43DA-9C1F-A76C5831A693Q38229320-99EDF700-4B8D-402C-8758-7C437F6CAE3AQ38286355-307594AE-1298-47ED-8683-88979A428C45Q38584289-7CF5EA8A-D985-4778-9EE3-969704F35676Q42024851-6269A43A-34ED-4807-BCAD-A782ACDA0436Q42241628-3DFAA0C4-9F6E-4DB5-94E8-2785EF3892C3Q43037191-0CAE364A-21B6-41D8-8341-2ECBF61D27E4Q43039673-AC70A007-9828-47DE-AC06-6D2C583BEC70Q43041850-1303F31F-179E-4E92-AC2A-2B2DC51E75CCQ45252446-9B045111-7862-45D3-8E0D-0334EC42FFE3Q58704499-562C325E-1588-4BD5-BB49-7979251A256C
P2860
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@en
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@nl
type
label
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@en
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@nl
prefLabel
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@en
Effect of calcineurin inhibito ...... s C virus-positive recipients.
@nl
P2093
P1433
P1476
Effect of calcineurin inhibito ...... is C virus-positive recipients
@en
P2093
Angel Moya
Angel Rubin
Eugenia Pareja
Eva Montalva
Fernando San Juan
Manuel de Juan
Maria Yago
Marina Berenguer
Rafael López-Andujar
P304
P356
10.1097/TP.0B013E3181FA93FA
P577
2010-12-01T00:00:00Z